Oral anabolic androgenic steroid
Anadrol
Anadrol after one dose: 50% at ~9 h, 25% at 18 h, 12.5% at 27 h.
Drawn from the half-life in the app's model, ~9 h. The model's figures
- Compound
- Anadrol
- Symbol
- ADL
- Family
- Other steroids
- Parts
- 14
- References
- 16
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Oxymetholone, supplied as Anadrol-50 tablets, is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone.3,1 The US label, revised August 2004, describes oxymetholone as "a potent anabolic and androgenic drug".1 The label states that the tablets are indicated in the treatment of anemias caused by deficient red cell production and that acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond.1
A 2001 review by Pavlatos and colleagues in Clinical Therapeutics reports that oxymetholone has been studied for HIV-associated wasting, antithrombin III deficiency, pediatric growth impairment and damaged myocardium, "with varying degrees of success".3 The US National Toxicology Program lists oxymetholone as "reasonably anticipated to be a human carcinogen" on the basis of limited evidence in humans.4
How it works
Sources in this part
What the label states
The label states that nitrogen balance is improved with anabolic agents but only when there is sufficient intake of calories and protein.1 It also states that whether this positive nitrogen balance is of primary benefit in the utilization of protein-building dietary substances has not been established.1 According to the label, oxymetholone enhances the production and urinary excretion of erythropoietin in patients with anemias due to bone marrow failure and often stimulates erythropoiesis in anemias due to deficient red cell production.1 The label adds that complete dissociation of anabolic and androgenic effects has not been achieved and that anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.1
In cells
Vieri and colleagues, at RWTH Aachen University, treated mononuclear cells from peripheral blood and bone marrow of four people with dyskeratosis congenita in culture with danazol, oxymetholone or nandrolone (International Journal of Molecular Sciences, 2020).5 In the three people with TERC or TERT mutations the authors found no substantial differences in the activity of the three agents, and all three produced comparable improvements of proliferation rates and degrees of telomere elongation (the improvement in cell numbers was temporary); increased TERT expression was shown with danazol and oxymetholone, and the effects on proliferation of bone marrow progenitors could be reversed by tamoxifen.5 The fourth person, with a DKC1 mutation, showed no response to any of the three agents (no gain in colony formation, no telomere elongation).5 The study reports no external funding, and two authors receive scientific support from Repeat Dx; it is a laboratory study of cells from four people, not a result of treating people.5
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~9 h
- Bioavailability
- 95%
- Typical dose
- 50–100 mg/day
- Route
- Oral
- Time to peak
- ~2 h
| Measure | App figure | Source figure |
|---|---|---|
| Half-life | ~9 h | No human half-life is stated in the US label copy, and the 2001 review states that few pharmacokinetic and tolerability studies were performed before oxymetholone's approval in the 1960s.1,3 |
| Bioavailability | 95% | No bioavailability figure is stated in the US label copy or in the plasma study; the label describes tablets for oral administration.1,6 |
| Time to peak | ~2 h | Cmax 18.8 ± 0.4 ng/mL and Tmax 210 ± 42.4 minutes (3.5 hours) in healthy volunteers after oral administration of 50 mg, reported by Cardoso and colleagues, Journal of Chromatography B, 2002.6 |
| Route | Oral | The label describes tablets for oral administration, each containing 50 mg.1 |
Cardoso and colleagues, at the doping-control laboratory (LABDOP) of the Federal University of Rio de Janeiro, gave these values while validating a gas chromatography-mass spectrometry method for oxymetholone in human plasma.6 The text read does not state the number of volunteers or a sponsor.
The chart below is an illustrative model built from the app's half-life of 9 hours and time to peak of 2 hours, not a measured curve, and the source figure for time to peak is 3.5 hours.6 Its two dosing schedules are the twice-daily and three-times-daily schedules of the 2003 HIV wasting trial, each 50 mg an intake.7
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Hengge and colleagues, 2003 (two papers that appear to describe one trial)7,10 | Randomised, double-blind, placebo-controlled, phase III; 16 weeks, then open-label.7 | 89 eugonadal HIV-positive women and men with wasting.7,10 | 50 mg twice or three times daily, or placebo, 16 weeks.7 | Weight gain 3.0 ± 0.5 kg (three times daily) and 3.5 ± 0.7 kg (twice daily) against 1.0 ± 0.7 kg on placebo (P < 0.05 each); AIDS paper: alanine aminotransferase above 5 times baseline in 35% (three times daily), 27% (twice daily) and no one on placebo; HIV Clinical Trials paper: ALT, AST or GGT above 5 times baseline in 43%, 25% and 8% on placebo.7,10 |
| Hengge and colleagues, 199611 | 30-week prospective pilot; random assignment to oxymetholone alone or with ketotifen, compared with 30 untreated matched controls; no sponsor stated in the text read.11 | 30 patients with HIV-1 infection and chronic cachexia, and 30 controls.11 | Dose not stated in the text read; 30 weeks. | Average weight gain at peak 8.2 (SD 6.2) kg with oxymetholone alone (n = 14, P < 0.001) and 6.1 (SD 4.6) kg with oxymetholone plus ketotifen (n = 16, P < 0.005), against an average weight loss of 1.8 (SD 0.7) kg in untreated controls.11 |
| Aramwit and colleagues, 20098 | Randomised, double-blind, placebo-controlled; all patients were encouraged to walk at least one kilometer daily.8 | 44 patients on maintenance hemodialysis (21 treatment, 23 control), mean age 43.5 years.8 | 50 mg orally twice daily, or placebo, 24 weeks.8 | HOMA index and body fat mass significantly decreased in the treatment group compared with the control group (P < 0.05 each); change in fat free mass 3.24 ± 1.74 kg against 0.65 ± 1.21 kg in controls (P < 0.05); elevated liver enzymes in 2 treated patients (9.52%).8 |
| Aramwit and colleagues, 201012 | Double-blind, placebo-controlled; both groups also received recombinant human erythropoietin.12 | 24 people on continuous ambulatory peritoneal dialysis (11 treatment, 13 placebo).12 | 50 mg twice daily with erythropoietin, or placebo with erythropoietin, 6 months.12 | Hematocrit 38.1 ± 1.0% against 32.8 ± 0.9% and hemoglobin 12.9 ± 0.3 against 11.0 ± 0.3 g/dL (P = 0.001 each); a rise in liver enzymes was the main side effect in the treatment group.12 |
| Chaipokam and Rojnuckarin, 20259 | Cohort, single center in Thailand (111 recruited prospectively, 34 reviewed retrospectively); no funding.9 | 110 evaluable patients aged 15 or over with aplastic anemia, mean age 63.4 years.9 | Median 150 mg a day (IQR 100 to 150); response at month 6.9 | Overall response 56.4% (95% CI 46.6 to 65.8); 17 stopped for side effects; 24 of 110 died; 5-year overall survival 77.4%.9 |
| Pengthina and Saelue, 202213 | Retrospective cohort, propensity score matching; the authors declare no conflict of interest.13 | 103 patients aged 15 or over with aplastic anemia, 74 matched (37 nonsevere, 37 severe or very severe).13 | Median 100 mg a day (nonsevere) and 150 mg a day (severe or very severe) before matching; median follow-up 2.7 years.13 | One-year overall response 54.1% (nonsevere) and 13.5% (severe or very severe), P < 0.001; overall survival 59.5% and 37.8% (P = 0.051); median survival 7.0 and 1.8 years (P = 0.045); 16 of 40 responders relapsed.13 |
Deeper analysis: HIV wasting trial (Hengge and colleagues, 2003)
Hengge and colleagues, from the Department of Dermatology of the University of Essen, Germany (AIDS paper) and the University of Düsseldorf (HIV Clinical Trials paper), reported what appears to be one double-blind, randomized, placebo-controlled phase III trial of oxymetholone in eugonadal HIV-positive women and men with wasting, in AIDS and in HIV Clinical Trials in 2003.7 The 89 participants were assigned to 50 mg twice or three times daily or to placebo for 16 weeks, followed by open-label treatment, and the endpoints were body weight, bioimpedance measurements, quality of life parameters and appetite.7 Weight rose 3.0 ± 0.5 kg with three-times-daily dosing and 3.5 ± 0.7 kg with twice-daily dosing against 1.0 ± 0.7 kg on placebo.7 Body cell mass increased 3.8 ± 0.4 kg in the twice-daily group (P < 0.0001) and 2.1 ± 0.6 kg in the three-times-daily group (P < 0.005).7
The authors state that "the most important adverse event was liver-associated toxicity".7 In the HIV Clinical Trials paper, other adverse events were not increased over placebo, and the authors conclude that the twice-daily regimen (100 mg a day) appeared equally effective as the three-times-daily regimen (150 mg a day) in terms of weight gain, lean body mass and body cell mass, with less liver toxicity.10 The AIDS paper concludes "less, but still significant liver toxicity".7 The two records name no sponsor and give no limitations of the authors' own, and do not describe the open-label phase further.
Deeper analysis: aplastic anemia cohorts (Chaipokam and Rojnuckarin, 2025; Pengthina and Saelue, 2022)
Chaipokam and Rojnuckarin, Annals of Hematology, 2025, analysed patients aged 15 or over in Thailand with aplastic anemia treated with oxymetholone alone for at least 30 days between 2013 and 2023.9 Of 145 patients enrolled, those with under 30 days of androgen treatment were excluded (14 losses to follow-up, 10 deaths from aplastic anemia and two deaths from other causes) and nine more were lost to follow-up between 30 and 180 days, leaving 110 for evaluation, with a mean age of 63.4 years and 58.2% female.9 The overall response at month 6 was 56.4%, with deaths counted as no response and a median time to transfusion independence of 11.8 weeks.9 Seventeen patients stopped treatment for side effects, 14 for liver enzyme elevations above three times the upper limit of normal and three for severe fluid retention or congestive heart failure; the summary gives their share as 17.9% and the results text as 15.5%, and the summary says 15 of the 17 were for hepatitis.9 Hepatitis occurred in 20.9%, edema in 26.4% and gastrointestinal toxicity in 5.5%, androgenic side effects in 55.5%, and 5-year overall survival was 77.4%, 94.5% in responders and 48.3% in non-responders.9 A total of 24 of the 110 patients died (infections 9, central nervous system bleeding 5, gastrointestinal bleeding 2, unknown causes 3, causes unrelated to aplastic anemia 5), and six responders (9.7%) lost their response at a median of 17 months.9 The authors state: "The limitation of this study is the single center at the specific region that may reduce generalizability," and that they might have included patients with inherited bone marrow failure because paroxysmal nocturnal hemoglobinuria clone detection and genetic examination were not routinely performed; they report no funding and no competing interests.9
Pengthina and Saelue, Journal of Blood Medicine, 2022, reviewed 103 patients aged 15 or over with acquired aplastic anemia given oxymetholone between 2004 and 2018 at Songklanagarind Hospital, Prince of Songkla University, Thailand and matched 74 on sex, age and interval from first symptom to treatment.13 One-year overall response was 54.1% in nonsevere and 13.5% in severe or very severe disease (P < 0.001), overall survival was 59.5% and 37.8% (P = 0.051), median survival was 7.0 and 1.8 years (P = 0.045), 16 of 40 responders relapsed, and 38 patients (51.4%) died during the study period.13 The authors give the small sample size and the retrospective design as limitations.13
Deeper analysis: trials in people on dialysis (Aramwit and colleagues, 2009 and 2010)
Aramwit and colleagues, at the Faculty of Pharmaceutical Sciences of Chulalongkorn University, Bangkok, ran two placebo-controlled trials of 50 mg twice daily in people on dialysis.8,12 In 44 people on maintenance hemodialysis over 24 weeks, all encouraged to walk at least one kilometer daily, the HOMA index and body fat mass were significantly decreased in the treatment group compared with the control group (P < 0.05 each), and the authors concluded that the increase in insulin sensitivity depended on changes in fat free mass and fat mass.8 The records name no sponsor and state no limitations of the authors' own; the groups were 21 and 23 in one trial and 11 and 13 in the other.8,12
Doses reported in studies and on the label
The app's typical dose range is 50 to 100 mg a day. The label states doses by body weight, 1 to 5 mg per kilogram per day in children and adults, with 1 to 2 mg per kilogram per day described as the usual effective dose, adds that higher doses may be required and that the dose is to be individualized, and gives a minimum trial of three to six months; most studies in the table gave 100 to 150 mg a day as fixed doses or as medians.1,7,9,13
| Source | Dose | Frequency | Length |
|---|---|---|---|
| US label, children and adults1 | 1 to 5 mg/kg body weight a day; usual effective dose 1 to 2 mg/kg a day1 | Per day1 | Minimum trial of three to six months, per the label1 |
| Hengge and colleagues, 20037 | 50 mg an intake (100 or 150 mg a day) | Twice or three times daily | 16 weeks, then open-label |
| Aramwit and colleagues, 20098 | 50 mg an intake (100 mg a day) | Twice daily | 24 weeks |
| Aramwit and colleagues, 201012 | 50 mg an intake (100 mg a day) | Twice daily | 6 months |
| Chaipokam and Rojnuckarin, 20259 | Initial 150 mg a day; 50 to 100 mg a day in people with lower kidney function or liver disease; median 150 mg a day (IQR 100 to 150)9 | Per day | Response assessed at 6 months; the protocol switched treatment if no response after 6 months9 |
| Pengthina and Saelue, 202213 | Median 150 mg a day (severe or very severe) and 100 mg a day (nonsevere) before matching | Per day | Median follow-up 2.7 years |
Side effects reported
The label's warnings, written for androgenic anabolic steroids as a class, describe peliosis hepatis, "a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts", and state that these cysts have sometimes been associated with liver failure and that withdrawal of the drug usually results in complete disappearance of the lesions, and that these cysts are often not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops.1 They also describe liver cell tumors, "most often these tumors are benign and androgen-dependent, but fatal malignant tumors have been reported", with the label saying hepatic tumors associated with androgens or anabolic steroids may be silent until life-threatening intra-abdominal hemorrhage develops, and blood lipid changes including decreased high density lipoprotein and sometimes increased low density lipoprotein.1 The label states that cholestatic hepatitis and jaundice occur with 17-alpha-alkylated androgens at relatively low doses, that drug-induced jaundice is usually reversible when the medication is discontinued, and that continued therapy has been associated with hepatic coma and death.1
Its adverse reactions section lists, in postpubertal men, inhibition of testicular function, testicular atrophy and oligospermia, in women clitoral enlargement and menstrual irregularities, and, in both sexes, increased or decreased libido.1 The label reports that leukemia has been observed in patients with aplastic anemia treated with oxymetholone and that its role, if any, is unclear because malignant transformation has been seen in patients with blood dyscrasias and leukemia has been reported in patients with aplastic anemia who have not been treated with oxymetholone.1 It states that oxymetholone can cause fetal harm in pregnancy, that anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children, and that the pregnancy category is X.1
In the matched retrospective cohort of 74, the adverse effects listed were infection (64.8%), impaired liver function (40.5%), bleeding (13.5%) and virilization (12.1%), and moderate to severe impaired liver function was the leading cause of treatment discontinuation (62.5%).13
Case reports describe a 26-year-old man who presented on day 29 after self-administering oxymetholone 50 mg a day with intramuscular testosterone enanthate 250 mg a week; peak total bilirubin was 24.6 mg/dL, and it fell 69.1% by day 57 and 91.5% by day 85 after both were withdrawn on day 30.14 Taha and colleagues write that the concomitant testosterone and absent chemical verification of the products precluded definitive single-agent attribution, and that the course supports oxymetholone as the principal suspect.14 They add that recovery cannot be attributed to supportive pharmacotherapy (ursodeoxycholic acid and antipruritic therapies) in this uncontrolled case.14 Chu and colleagues, Journal of the Neurological Sciences, 2001, reported cerebral venous thrombosis with a tentorial subdural hematoma in a 40-year-old woman with aplastic anemia who had taken oxymetholone for 2 years, with symptoms disappearing after it was discontinued.15
The National Toxicology Program writes, citing IARC 1977, that in numerous case reports liver tumors have been reported in patients with aplastic anemia, Fanconi anemia, paroxysmal nocturnal hemoglobinuria or other disorders treated, usually for long periods, with oxymetholone alone or in combination with other androgenic drugs, and that "a causal relationship cannot be firmly established".4 In a rat study cited by the program, oxymetholone given by stomach tube increased the combined incidence of benign and malignant liver tumors in female rats, and benign lung tumors and benign and malignant skin tumors in female rats were also considered related to exposure.4
Bloodwork and markers
Sources in this part
The app lists liver enzymes, lipids and hematocrit as markers for oxymetholone. The label's precautions call for periodic liver function tests because of the hepatotoxicity associated with 17-alpha-alkylated androgens, periodic serum lipids and high density lipoprotein cholesterol, and periodic hemoglobin and hematocrit checks for polycythemia in patients receiving high doses of anabolics.1
Regulatory and anti-doping status
The label states that Anadrol tablets are considered a controlled substance and are listed in Schedule III.1 The US Code of Federal Regulations lists oxymetholone in Schedule III under 21 CFR 1308.13(f), the anabolic steroids paragraph.16
The WADA 2026 Prohibited List, in effect from 1 January 2026, names oxymetholone among the anabolic androgenic steroids in S1.1 when administered exogenously, a class that is prohibited at all times, in and out of competition, and whose substances are all non-Specified Substances.2 The National Toxicology Program's Report on Carcinogens, Fifteenth Edition, first listed oxymetholone in 1980 and states that it is marketed as a human prescription drug for the treatment of anemia caused by deficient red blood cell production.4
Storage and handling
Sources in this part
The label states that tablets are supplied in bottles of 100 white scored tablets imprinted with 8633 and UNIMED and are to be stored at controlled room temperature, 20° to 25°C (68° to 77°F).1
What is not known
Sources in this part
The label copy read is dated August 2004, so any later change to the US label is not covered by the label statements above.1 No human half-life or oral bioavailability figure is stated in the label copy, the 2001 review summary or the plasma assay paper, and the plasma figures reported are a Cmax of 18.8 ng/mL and a time to peak of 210 minutes after 50 mg.6 The sources read do not state whether oxymetholone is converted to estrogen by aromatase, and the label's list of adverse reactions includes gynecomastia.1 The label states that clinical studies of Anadrol tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.1 The National Toxicology Program states that the evidence for liver tumors in people comes from case reports, and the Strong Evidence grade shown with this compound is the app's own grade, not a conclusion of the sources.4
Frequently asked questions
What is the half-life of Anadrol?
What is Anadrol used for?
The US label states that Anadrol tablets are indicated in the treatment of anemias caused by deficient red cell production.1
Is Anadrol a controlled substance?
Is Anadrol banned by WADA?
Yes: the WADA 2026 Prohibited List names oxymetholone among the anabolic androgenic steroids in S1.1 when administered exogenously, prohibited at all times, in and out of competition.2
Does Anadrol affect the liver?
The US label states that cholestatic hepatitis and jaundice occur with 17-alpha-alkylated androgens at relatively low doses and lists peliosis hepatis and liver cell tumors among reported conditions.1 In the 89-person HIV wasting trial, 35% on three-times-daily dosing and 27% on twice-daily dosing had alanine aminotransferase above 5 times baseline against none on placebo in the AIDS paper, while the HIV Clinical Trials paper gives 43%, 25% and 8% on placebo for a rise in ALT, AST or GGT, and in 110 patients with aplastic anemia hepatitis occurred in 20.9%.7,10,9
What did the HIV wasting trial of Anadrol find?
What did Anadrol studies in aplastic anemia find?
In 110 patients aged 15 or over in Thailand treated with oxymetholone alone, the overall response at month 6 was 56.4% (95% CI 46.6 to 65.8), 17 patients stopped treatment for side effects and 24 died during follow-up.9 In a retrospective cohort of 74 matched patients aged 15 or over, one-year overall response was 54.1% in nonsevere and 13.5% in severe or very severe disease, and 38 (51.4%) died during the study period.13
Is Anadrol listed as a carcinogen?
Guides, tools and comparisons
References
- Unimed Pharmaceuticals. ANADROL-50 (oxymetholone) tablets, Rev Aug 2004 (copy posted by FDA, archived). US label (2004)
- World Anti-Doping Agency. World Anti-Doping Code International Standard, Prohibited List 2026, in effect 1 January 2026. WADA Prohibited List 2026
- Pavlatos AM, et al. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 2001. PMID 11440282
- National Toxicology Program. Oxymetholone. Report on Carcinogens, Fifteenth Edition. NTP Report on Carcinogens
- Vieri M, et al. Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita. Int J Mol Sci 2020. PMC7584039
- Cardoso CR, et al. Validation of the determination of oxymetholone in human plasma analysis using gas chromatography-mass spectrometry. Application to pharmacokinetic studies. J Chromatogr B 2002. PMID 12101054
- Hengge UR, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 2003. PMID 12646793
- Aramwit P, et al. Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. Clin Nephrol 2009. PMID 19356374
- Chaipokam J, Rojnuckarin P. Good response to oxymetholone in adult aplastic anemia. Ann Hematol 2025. PMC12334477
- Hengge UR, et al. Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women. HIV Clin Trials 2003. PMID 12815555
- Hengge UR, et al. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996. PMID 8785183
- Aramwit P, et al. The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. Int J Clin Pharmacol Ther 2010. PMID 21084036
- Pengthina W, Saelue P. Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis. J Blood Med 2022. PMC9741824
- Taha HM, et al. Oxymetholone-Associated Cholestatic Drug-Induced Liver Injury With Profound Hyperbilirubinaemia: A Longitudinal Case Report. Case Rep Hepatol 2026. PMID 42729935
- Chu K, et al. Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy. J Neurol Sci 2001. PMID 11266687
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13